TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer

被引：0
作者：
D. Ferraro
D. Goldstein
R. L. O’Connell
J. R. Zalcberg
K. M. Sjoquist
N. C. Tebbutt
P. Grimison
S. McLachlan
L. L. Lipton
P. Vasey
V. J. Gebski
C. Aiken
M. Cronk
S. Ng
C. S. Karapetis
J. Shannon
机构：
[1] University of Sydney,National Health and Medical Research Council Clinical Trials Centre
[2] University of New South Wales,Prince of Wales Clinical School
[3] Monash University,Department of Epidemiology and Preventive Medicine
[4] Austin Health,Haematology and Oncology Clinics of Australasia
[5] Chris O’Brien Lifehouse,Department of Medical Oncology
[6] St Vincents Hospital,Department of Pathology
[7] University of Melbourne,undefined
[8] Western Health,undefined
[9] Wesley Medical Centre,undefined
[10] Nambour General Hospital,undefined
[11] Flinders University,undefined
[12] Nepean Cancer Care Centre,undefined
[13] University of Melbourne,undefined
[14] Sir Charles Gairdner Hospital,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2016年 / 78卷
关键词：
Biliary tract cancer; KRAS; Panitumumab; Chemotherapy; Phase II trial; Cancer antigen 19.9;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：361 / 367
页数：6
相关论文
共 188 条
  • [1] Wade TP(1997)Experience with distal bile duct cancers in U.S. Veterans Affairs hospitals: 1987–1991 J Surg Oncol 64 242-245
  • [2] Prasad CN(2015)Survival in patients with primary liver cancer, gallbladder and extrahepatic biliary tract cancer and pancreatic cancer in Europe 1999–2007: results of EUROCARE-5 Eur J Cancer 51 2169-2178
  • [3] Virgo KS(2010)Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer N Engl J Med 362 1273-1281
  • [4] Johnson FE(2008)EGFR antagonists in cancer treatment N Engl J Med 358 1160-1174
  • [5] Lepage C(2010)Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study Lancet Oncol 11 1142-1148
  • [6] Capocaccia R(2013)A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma Ann Oncol 24 3061-3065
  • [7] Hackl M(2012)Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer Ann Oncol 23 2341-2346
  • [8] Lemmens V(2012)Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study Lancet Oncol 13 181-188
  • [9] Molina E(2010)Fixed-dose-rate gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas Cancer Chemother Pharmacol 67 519-525
  • [10] Pierannunzio D(2007)Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer Dig Dis Sci 53 564-570
12345678910